Genetic abnormalities that involve the PDGFRA gene cause a type of blood cell cancer called PDGFRA-associated chronic eosinophilic leukemia. The most common of these genetic abnormalities is a deletion of genetic material from chromosome 4 that brings together parts of two genes, FIP1L1 and PDGFRA, creating the FIP1L1-PDGFRA fusion gene. Occasionally, genes other than FIP1L1 are fused with the PDGFRA gene via a translocation between chromosome 4q12 and a partner chromosome. This gene is also involved in systemic mastocytosis and chronic eosinophilic leukemia. Patients carrying the FIP1L1-PDGFRA fusion show an excellent response to low-dose imatinib mesylate therapy.
This test can be ordered individually or as part of an Eosinophilia FISH Panel. See the individual panel test for more details.
Bone marrow aspirate:
Collect bone marrow aspirate in a sterile Sodium heparin (Na hep) syringe and transfer to a sterile vial/tube
- or -
Collect bone marrow in sterile syringe (non-heparinized) and transfer to a Dk green Sodium heparin (Na hep), no gel
Transfer aspirate from syringe to transport container.
Submit entire specimen unspun
Bone marrow core:
Submit in sterile tube/cup filled with sterile culture medium, sterile Hanks Balance Salt Solution (HBSS) or sterile saline
Whole blood:
Immediately following collection, mix sample thoroughly by gently inverting 8 - 10 times to prevent clotting.
Submit entire specimen unspun
AHL Cytogenetics Oncology Request
Ambient
Fluorescence in situ hybridization (FISH)
Normal or Abnormal with interpretation